Organon Orgaran Stroke Study Cited For Lack of Proper Monitoring By FDA
Executive Summary
An Organon-sponsored ischemic stroke study for its low molecular weight heparin product Orgaran has been cited for lack of supervision and monitoring by FDA's Bioresearch Monitoring Program.
You may also be interested in...
Merck-Medco Las Vegas Pharmacy Is At Center Of “Whistleblower” Case
Merck's ownership of Medco has resulted in a significant decline in sound pharmacy practices at the PBM's mail order facilities, two ex-employees charge in a "whistleblower" suit unsealed June 23
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011